A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors

Xentuzumab is an insulin‐like growth factor (IGF) ligand‐neutralizing antibody. This phase 1 trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged ≥20 y old with solid tumors that were refractory or not amenable to standard therapy were enrolled. Patients received xentuzuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Kuboki, Yasutoshi, Naito, Yoichi, Ishida, Masahiro, Tanaka, Tetsuya, Takeuchi, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898728/
https://www.ncbi.nlm.nih.gov/pubmed/34870878
http://dx.doi.org/10.1111/cas.15231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898728/
https://www.ncbi.nlm.nih.gov/pubmed/34870878
http://dx.doi.org/10.1111/cas.15231

Ejemplares similares